A Study of Distal Jejunal-release Dextrose in Obese Participants

• Status: Not yet recruiting
• Trial end date: 2023-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aphaia Pharma US LLC

Criteria

Inclusion Criteria:

• Body mass index 30.0-39.9 kg/m^2 and/or waist circumference: men >102 cm, women >88 cm

• Stable body weight: gain or loss in body weight ≤5 kg over last 3 months

• Obese participants with or without one or more of the following conditions:

1. NAFLD - simple steatosis based on a FibroScan CAP™ test result at screening (CAP Score ≥238 decibel-milliwatts (dB/m) (Steatosis Grades 1-3) with no or mild fibrosis (F0-F1 fibrosis Score)

2. NASH - steatohepatitis based on FibroScan fibrosis Score at screening (≥7.5 kPa and <14 kPa (Stage F2-F3)

3. Confirmed medical history of metabolic syndrome

4. Homeostatic Model Assessment of Insulin Resistance (HOMA IR) Score ≥2

5. Confirmed medical history of type 2 diabetes mellitus (T2DM) diagnosis or HbA1c ≥7.0 and <11 (based on screening values)

6. High total cholesterol ≥240 mg/dL (based on screening values)

7. Hypertension (participants with Stage 1 hypertension (systolic blood pressure [SBP] ≥130 mmHg <180 mmHg, diastolic blood pressure [DBP] ≥80 mmHg <110 mmHg) (based on screening values)

• If on medication to manage endocrine/metabolic conditions, must be on stable doses of medication ≥3 months prior to screening:

1. Participants with T2DM may be treated with either diet and exercise alone, metformin, sulphonylurea, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and bromocriptine quick-release (QR) as single agents or combination therapy.

2. As lipid-lowering medication participants may be treated with statins and fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, or supplements like omega-3-fatty acids.

3. As antihypertensive medication participants may be treated with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II-inhibitors, diuretics, or calcium channel blockers.

• Normal GI function, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study

Exclusion Criteria:

• Incomplete Coronavirus Disease of 2019 (COVID-19) vaccination

• Treatment with weight loss medications in the past 3 months

• Proven history of bulimia or anorexia nervosa

• Treatment with injectable antidiabetic medications in the last 3 months (e.g. Glucagon-like peptide-1 [GLP-1] receptor agonists, insulin)

• Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months

• NASH with cirrhosis (fibrosis Score=F4 (≥14 kPa) as determined by screening FibroScan

• Confirmed medical history of liver cirrhosis, cholestatic disease, alcohol-related liver disease

• Type 1 diabetes mellitus, HbA1c ≥11, fasting plasma glucose levels ≥270 mg/dL

• Proliferative retinopathy or maculopathy

• Abnormal liver function tests:

1. Transaminases:

• Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥5 x upper limit of normal (ULN) for participants with NAFLD or NASH (as determined by screening FibroScan)

• ALT/AST ≥2.5 x ULN for participants without NAFLD or NASH (as determined by screening FibroScan)

2. Alkaline phosphatase (ALK) ≥2.5 x ULN

3. Total bilirubin ≥2 x ULN

• Stage 4 hypertension (SBP ≥180, DBP ≥110)

• History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematologic, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator does not consider a disqualification for participation in the study